Oncolys Biopharma has announced that the first patient has been enrolled in the expansion cohort and has started treatment in a Phase I Clinical Trial for Telomelysin (OBP-301) in combination with chemoradiation for advanced esophageal or gastro-esophageal cancer. The study is being conducted by NRG Oncology and is sponsored by the National Cancer Institute. The objective of the trial is to evaluate the safety and efficacy of Telomelysin when added to weekly carboplatin, paclitaxel, and radiation therapy for patients who are not candidates for surgery. The expansion cohort will enroll additional patients to further evaluate the safety and effectiveness of the treatment. In Japan, Telomelysin has already been shown to be effective in combination with radiation therapy for locally advanced esophageal cancer, and Oncolys plans to submit a New Drug Application to the Japanese regulatory authority by the end of 2024.
Thu, 02 Nov 2023 06:00:00 GMT | Marketscreener.com